 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"warfarin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: WARFARIN: clinical_studies: Table [0m[1;31m5[0m[31m: Prospective, Randomized, Open-Label, Positive-Controlled Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves Patients Treated [0m
[31mWith Warfarin Dipyridamole/Aspirin Pentoxifylline/Aspirin Event Thromboembolism [0m[1;31m2.2[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m8.6[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m7.9[0m[31m/[0m[1;31m100[0m[31m py Major Bleeding [0m[1;31m2.5[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m0[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m0.9[0m[31m/[0m[1;31m100[0m[31m py py = patient years In a prospective, [0m
[31mopen-label, clinical study comparing moderate [0m[1;31m([0m[31mINR [0m[1;31m2.65[0m[1;31m)[0m[31m versus high intensity [0m[1;31m([0m[31mINR [0m[1;31m9[0m[1;31m)[0m[31m warfarin therapies in [0m[1;31m258[0m[31m patients with mechanical prosthetic heart valves, thromboembolism occurred with similar[0m
[31mfrequency in the two groups [0m[1;31m([0m[1;31m4[0m[31m and [0m[1;31m3.7[0m[31m events per [0m[1;31m100[0m[31m patient years, respectively[0m[1;31m)[0m[31m. Major bleeding was more common in the high intensity group. WARFARIN: clinical_studies: The results of this study [0m
[31mare presented in Table [0m[1;31m6[0m[31m . Table [0m[1;31m6[0m[31m: Prospective, Open-Label Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves Event Moderate Warfarin Therapy INR [0m[1;31m2.65[0m[31m High Intensity [0m
[31mWarfarin Therapy INR [0m[1;31m9[0m[31m Thromboembolism [0m[1;31m4[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m3.7[0m[31m/[0m[1;31m100[0m[31m py Major Bleeding [0m[1;31m0.95[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m2.1[0m[31m/[0m[1;31m100[0m[31m py py = patient years In a randomized trial in [0m[1;31m210[0m[31m patients comparing two intensities of warfarin therapy [0m
[1;31m([0m[31mINR [0m[1;31m2[0m[31m to [0m[1;31m2.25[0m[31m vs. INR [0m[1;31m2.5[0m[31m to [0m[1;31m4[0m[1;31m)[0m[31m for a three month period following tissue heart valve replacement, thromboembolism occurred with similar frequency in the two groups [0m[1;31m([0m[31mmajor embolic events [0m[1;31m2[0m[31m% vs. [0m[1;31m1.9[0m[31m%,[0m
[31mrespectively, and minor embolic events [0m[1;31m10.8[0m[31m% vs. [0m[1;31m10.2[0m[31m%, respectively[0m[1;31m)[0m[31m. WARFARIN: clinical_studies: Major hemorrhages occurred in [0m[1;31m4.6[0m[31m% of patients in the higher intensity INR group compared to zero in [0m
[31mthe lower intensity INR group. [0m[1;31m14.3[0m[31m Myocardial Infarction WARIS [0m[1;31m([0m[31mThe Warfarin Re-Infarction Study[0m[1;31m)[0m[31m was a double-blind, randomized study of [0m[1;31m1214[0m[31m patients [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m weeks post-infarction treated with [0m
[31mwarfarin to a target INR of [0m[1;31m2.8[0m[31m to [0m[1;31m4.8[0m[31m. The primary endpoint was a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of[0m
[31mthe patients was [0m[1;31m37[0m[31m months. The results for each endpoint separately, including an analysis of vascular death, are provided in Table [0m[1;31m7[0m[31m . WARFARIN: clinical_studies: Table [0m[1;31m7[0m[31m: WARIS â€“ Endpoint Analysis [0m
[31mof Separate Events % Risk Warfarin Placebo Reduction Event [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m RR [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m [0m[1;31m([0m[31m p -value[0m[1;31m)[0m[31m Total Patient Years of Follow-up [0m[1;31m2018[0m[31m [0m[1;31m1944[0m[31m Total Mortality [0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m123[0m[31m [0m[1;31m([0m[1;31m6.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.76[0m[31m [0m
[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m0.97[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.030[0m[1;31m)[0m[31m Vascular Death [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m5.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.78[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m1.02[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m Recurrent MI [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: [0m
[31mclinical_studies: [0m[1;31m001[0m[1;31m)[0m[31m Cerebrovascular Event [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m [0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.002[0m[1;31m)[0m[31m RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = Confidence interval; MI = Myocardial [0m
[31minfarction; py = patient years WARIS II [0m[1;31m([0m[31mThe Warfarin, Aspirin, Re-Infarction Study[0m[1;31m)[0m[31m was an open-label, randomized study of [0m[1;31m3630[0m[31m patients hospitalized for acute myocardial infarction treated with [0m
[31mwarfarin to a target INR [0m[1;31m2.8[0m[31m to [0m[1;31m4.2[0m[31m, aspirin [0m[1;31m160[0m[31m mg per day, or warfarin to a target INR [0m[1;31m2[0m[31m to [0m[1;31m2.5[0m[31m plus aspirin [0m[1;31m75[0m[31m mg per day prior to hospital discharge. The primary endpoint was a composite of death,[0m
[31mnonfatal reinfarction, or thromboembolic stroke. WARFARIN: clinical_studies: The mean duration of observation was approximately [0m[1;31m4[0m[31m years. The results for WARIS II are provided in Table [0m[1;31m8[0m[31m . Table [0m[1;31m8[0m[31m: [0m
[31mWARIS II â€“ Distribution of Events According to Treatment Group Event Aspirin [0m[1;31m([0m[31mN = [0m[1;31m1206[0m[1;31m)[0m[31m Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1216[0m[1;31m)[0m[31m Aspirin plus Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1208[0m[1;31m)[0m[31m Rate Ratio [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m p -value No. of Events Major Bleeding a[0m
[1;31m8[0m[31m [0m[1;31m33[0m[31m [0m[1;31m28[0m[31m [0m[1;31m3.35[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m4.00[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Minor Bleeding d [0m[1;31m39[0m[31m [0m[1;31m103[0m[31m [0m[1;31m133[0m[31m [0m[1;31m3.21[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m2.55[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Composite Endpoints e [0m[1;31m241[0m[31m [0m[1;31m203[0m[31m [0m[1;31m181[0m[31m [0m[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m[1;31m0.95[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m c [0m[1;31m0[0m[31m. WARFARIN: [0m
[31mclinical_studies: [0m[1;31m001[0m[31m Reinfarction [0m[1;31m117[0m[31m [0m[1;31m90[0m[31m [0m[1;31m69[0m[31m [0m[1;31m0.56[0m[31m [0m[1;31m([0m[1;31m0.41[0m[31m to [0m[1;31m0.78[0m[1;31m)[0m[31m b [0m[1;31m<[0m[31m [0m[1;31m0.001[0m[31m [0m[1;31m0.74[0m[31m [0m[1;31m([0m[1;31m0.55[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Thromboembolic Stroke [0m[1;31m32[0m[31m [0m[1;31m17[0m[31m [0m[1;31m17[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.97[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Death [0m[1;31m92[0m[31m [0m[1;31m96[0m[31m [0m
[1;31m95[0m[31m [0m[1;31m0.82[0m[31m a Major bleeding episodes were defined as nonfatal cerebral hemorrhage or bleeding necessitating surgical intervention or blood transfusion. b The rate ratio is for aspirin plus warfarin as [0m
[31mcompared with aspirin. c The rate ratio is for warfarin as compared with aspirin. d Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood [0m
[31mtransfusion. WARFARIN: clinical_studies: e Includes death, nonfatal reinfarction, and thromboembolic cerebral stroke. CI = confidence interval ND = not determined There were approximately four times [0m
[31mas many major bleeding episodes in the two groups receiving warfarin than in the group receiving aspirin alone. Major bleeding episodes were not more frequent among patients receiving aspirin plus [0m
[31mwarfarin than among those receiving warfarin alone, but the incidence of minor bleeding episodes was higher in the combined therapy group.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism [0m[1;31m([0m[31mPE[0m[1;31m)[0m[31m. [0m
[31mProphylaxis and treatment of thromboembolic complications associated with atrial fibrillation [0m[1;31m([0m[31mAF[0m[1;31m)[0m[31m and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction [0m
[1;31m([0m[31mMI[0m[1;31m)[0m[31m, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor [0m
[31mdoes it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary [0m
[31mthromboembolic complications that may result in serious and possibly fatal sequelae. WARFARIN: indications_and_usage: Warfarin sodium tablets are a vitamin K antagonist indicated for: Prophylaxis and [0m
[31mtreatment of venous thrombosis and its extension, pulmonary embolism [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve [0m
[31mreplacement [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Limitations of [0m
[31mUse Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: dosage_and_administration: [0m[1;31m2[0m[31m Recommended Target INR Ranges and Durations for Individual Indications An INR of greater than [0m[1;31m4[0m[31m appears to provide no additional therapeutic benefit in [0m
[31mmost patients and is associated with a higher risk of bleeding. Venous Thromboembolism [0m[1;31m([0m[31mincluding deep venous thrombosis [0m[1;31m[[0m[31mDVT[0m[1;31m][0m[31m and PE[0m[1;31m)[0m[31m Adjust the warfarin dose to maintain a target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mINR [0m
[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m for all treatment durations. The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient [0m[1;31m([0m[31mreversible[0m[1;31m)[0m[31m risk factor, treatment [0m
[31mwith warfarin for [0m[1;31m3[0m[31m months is recommended. For patients with an unprovoked DVT or PE, treatment with warfarin is recommended for at least [0m[1;31m3[0m[31m months. After [0m[1;31m3[0m[31m months of therapy, evaluate the risk-benefit[0m
[31mratio of long-term treatment for the individual patient. WARFARIN: dosage_and_administration: For patients with two episodes of unprovoked DVT or PE, long-term treatment with warfarin is recommended. [0m
[31mFor a patient receiving long-term anticoagulant treatment, periodically reassess the risk-benefit ratio of continuing such treatment in the individual patient. Atrial Fibrillation In patients with [0m
[31mnon-valvular AF, anticoagulate with warfarin to target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m. In patients with non-valvular AF that is persistent or paroxysmal and at high risk of stroke [0m[1;31m([0m[31mi.e., having any of the[0m
[31mfollowing features: prior ischemic stroke, transient ischemic attack, or systemic embolism, or [0m[1;31m2[0m[31m of the following risk factors: age greater than [0m[1;31m75[0m[31m years, moderately or severely impaired left [0m
[31mventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus[0m[1;31m)[0m[31m, long-term anticoagulation with warfarin is recommended. WARFARIN: dosage_and_administration: In [0m
[31mpatients with non-valvular AF that is persistent or paroxysmal and at an intermediate risk of ischemic stroke [0m[1;31m([0m[31mi.e., having [0m[1;31m1[0m[31m of the following risk factors: age greater than [0m[1;31m75[0m[31m years, moderately or [0m
[31mseverely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus[0m[1;31m)[0m[31m, long-term anticoagulation with warfarin is recommended. For patients with AF [0m
[31mand mitral stenosis, long-term anticoagulation with warfarin is recommended. For patients with AF and prosthetic heart valves, long-term anticoagulation with warfarin is recommended; the target INR [0m
[31mmay be increased and aspirin added depending on valve type and position, and on patient factors. WARFARIN: dosage_and_administration: Mechanical and Bioprosthetic Heart Valves For patients with a [0m
[31mbileaflet mechanical valve or a Medtronic Hall [0m[1;31m([0m[31mMinneapolis, MN[0m[1;31m)[0m[31m tilting disk valve in the aortic position who are in sinus rhythm and without left atrial enlargement, therapy with warfarin to a [0m
[31mtarget INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m is recommended. For patients with tilting disk valves and bileaflet mechanical valves in the mitral position, therapy with warfarin to a target INR of [0m[1;31m3[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2.5[0m[31m [0m
[31mto [0m[1;31m3.5[0m[1;31m)[0m[31m is recommended. For patients with caged ball or caged disk valves, therapy with warfarin to a target INR of [0m[1;31m3[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2.5[0m[31m to [0m[1;31m3.5[0m[1;31m)[0m[31m is recommended. For patients with a bioprosthetic valve in the[0m
[31mmitral position, therapy with warfarin to a target INR of [0m[1;31m2[0m[31m. WARFARIN: dosage_and_administration: [0m[1;31m5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m for the first [0m[1;31m3[0m[31m months after valve insertion is recommended. If additional risk [0m
[31mfactors for thromboembolism are present [0m[1;31m([0m[31mAF, previous thromboembolism, left ventricular dysfunction[0m[1;31m)[0m[31m, a target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m is recommended. Post-Myocardial Infarction For high-risk [0m
[31mpatients with MI [0m[1;31m([0m[31me.g., those with a large anterior MI, those with significant heart failure, those with intracardiac thrombus visible on transthoracic echocardiography, those with AF, and those with [0m
[31ma history of a thromboembolic event[0m[1;31m)[0m[31m, therapy with combined moderate-intensity [0m[1;31m([0m[31mINR, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m warfarin plus low-dose aspirin [0m[1;31m([0m[31mâ‰¤ [0m[1;31m100[0m[31m mg/day[0m[1;31m)[0m[31m for at least [0m[1;31m3[0m[31m months after the MI is recommended. WARFARIN: [0m
[31mdosage_and_administration: Recurrent Systemic Embolism and Other Indications Oral anticoagulation therapy with warfarin has not been fully evaluated by clinical trials in patients with valvular [0m
[31mdisease associated with AF, patients with mitral stenosis, and patients with recurrent systemic embolism of unknown etiology. However, a moderate dose regimen [0m[1;31m([0m[31mINR [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m may be used for these [0m
[31mpatients. [0m[1;31m2.3[0m[31m Initial and Maintenance Dosing The appropriate initial dosing of warfarin sodium tablets varies widely for different patients. Not all factors responsible for warfarin dose variability [0m
[31mare known, and the initial dose is influenced by: Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities Genetic factors [0m[1;31m([0m[31mCYP2C9 and VKORC1 genotypes[0m[1;31m)[0m[31m [0m[31m [0m
[31mSelect the initial dose based on the expected maintenance dose, taking into account the above factors. WARFARIN: dosage_and_administration: Modify this dose based on consideration of patient-specific [0m
[31mclinical factors. Consider lower initial and maintenance doses for elderly and/or debilitated patients and in Asian patients [0m[31m . Routine use of loading doses is not recommended as this practice may [0m
[31mincrease hemorrhagic and other complications and does not offer more rapid protection against clot formation. Individualize the duration of therapy for each patient. In general, anticoagulant therapy [0m
[31mshould be continued until the danger of thrombosis and embolism has passed [0m[31m . Dosing Recommendations without Consideration of Genotype If the patientâ€™s CYP2C9 and VKORC1 genotypes are not known, the [0m
[31minitial dose of warfarin sodium tablets is usually [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m mg once daily.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies_table: [0m[1;31m02[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>Recurrent [0m
[31mMI <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m
[1;31m001[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>Cerebrovascular Event <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" [0m
[31mToprule"[0m[31m><paragraph>[0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m[1;31m002[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"5"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = [0m
[31mConfidence interval; MI = Myocardial infarction; py = patient years <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:WARFARIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Warfarin is indicated for the reduction in the risk of death, recurrent myocardial infarction [0m[1;32m([0m[32mMI[0m[1;32m)[0m[32m, and thromboembolic events such as stroke or systemic embolization after myocardial [0m
[32minfarction. Clinical studies, such as the Warfarin Re-Infarction Study [0m[1;32m([0m[32mWARIS[0m[1;32m)[0m[32m and the Warfarin, Aspirin, Re-Infarction Study [0m[1;32m([0m[32mWARIS II[0m[1;32m)[0m[32m, have shown that warfarin therapy can lead to a significant [0m
[32mreduction in the risk of recurrent myocardial infarction. For instance, in the WARIS study, patients treated with warfarin showed a [0m[1;32m34[0m[32m% risk reduction in recurrent MI compared to placebo.[0m

[32mSOURCE: WARFARIN label[0m
[32mEXTRACT_START_END: WARFARIN: clinical_studies: [0m[32m...[0m[32m recurrent myocardial infarction [0m[1;32m([0m[32mMI[0m[1;32m)[0m[32m, and thromboembolic events [0m[32m...[0m[32m EXTRACT_START_END: recurrent MI [0m[1;32m82[0m[32m [0m[1;32m([0m[1;32m4.1[0m[32m/[0m[1;32m100[0m[32m py[0m[1;32m)[0m[32m [0m[32m...[0m[32m [0m[1;32m34[0m[32m [0m[1;32m([0m[32mp = [0m[1;32m0.001[0m[1;32m)[0m[32m [0m[32m...[0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Warfarin is indicated for the reduction in the risk of [0m
[34mdeath, recurrent myocardial infarction [0m[1;34m([0m[34mMI[0m[1;34m)[0m[34m, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Clinical studies, such as the Warfarin Re-Infarction Study [0m
[1;34m([0m[34mWARIS[0m[1;34m)[0m[34m and the Warfarin, Aspirin, Re-Infarction Study [0m[1;34m([0m[34mWARIS II[0m[1;34m)[0m[34m, have shown that warfarin therapy can lead to a significant reduction in the risk of recurrent myocardial infarction. For instance, in[0m
[34mthe WARIS study, patients treated with warfarin showed a [0m[1;34m34[0m[34m% risk reduction in recurrent MI compared to placebo.[0m

[34mSOURCE: WARFARIN label[0m
[34mEXTRACT_START_END: WARFARIN: clinical_studies: [0m[34m...[0m[34m recurrent myocardial infarction [0m[1;34m([0m[34mMI[0m[1;34m)[0m[34m, and thromboembolic events [0m[34m...[0m[34m EXTRACT_START_END: recurrent MI [0m[1;34m82[0m[34m [0m[1;34m([0m[1;34m4.1[0m[34m/[0m[1;34m100[0m[34m py[0m[1;34m)[0m[34m [0m[34m...[0m[34m [0m[1;34m34[0m[34m [0m[1;34m([0m[34mp = [0m[1;34m0.001[0m[1;34m)[0m[34m [0m[34m...[0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether WARFARIN increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that WARFARIN is indicated for the reduction in the risk of death, recurrent myocardial infarction [0m[32m([0m[32mMI[0m[32m)[0m[32m, and thromboembolic events after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Clinical studies, such as the Warfarin Re-Infarction Study [0m[32m([0m[32mWARIS[0m[32m)[0m[32m and the Warfarin, Aspirin, Re-Infarction Study [0m[32m([0m[32mWARIS II[0m[32m)[0m[32m, have demonstrated that warfarin therapy can lead to a significant [0m
[32mreduction in the risk of recurrent myocardial infarction. In the WARIS study, patients treated with warfarin showed a 34% risk reduction in recurrent MI compared to placebo."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"WARFARIN decreases the risk of recurrent myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does WARFARIN increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether WARFARIN increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that WARFARIN is indicated for the reduction in the risk of death, recurrent myocardial infarction [0m[34m([0m[34mMI[0m[34m)[0m[34m, and thromboembolic events after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Clinical studies, such as the Warfarin Re-Infarction Study [0m[34m([0m[34mWARIS[0m[34m)[0m[34m and the Warfarin, Aspirin, Re-Infarction Study [0m[34m([0m[34mWARIS II[0m[34m)[0m[34m, have demonstrated that warfarin therapy can lead to a significant [0m
[34mreduction in the risk of recurrent myocardial infarction. In the WARIS study, patients treated with warfarin showed a 34% risk reduction in recurrent MI compared to placebo."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"WARFARIN decreases the risk of recurrent myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does WARFARIN increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether WARFARIN increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that WARFARIN is indicated for the reduction in the risk of death, recurrent myocardial infarction [0m[1;31m([0m[31mMI[0m[1;31m)[0m[31m, and thromboembolic events after myocardial infarction.[0m
[1;31m3[0m[31m. Clinical studies, such as the Warfarin Re-Infarction Study [0m[1;31m([0m[31mWARIS[0m[1;31m)[0m[31m and the Warfarin, Aspirin, Re-Infarction Study [0m[1;31m([0m[31mWARIS II[0m[1;31m)[0m[31m, have demonstrated that warfarin therapy can lead to a significant [0m
[31mreduction in the risk of recurrent myocardial infarction. In the WARIS study, patients treated with warfarin showed a [0m[1;31m34[0m[31m% risk reduction in recurrent MI compared to placebo.[0m
[31m        -----[0m
[31m        Final answer: WARFARIN decreases the risk of recurrent myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mWarfarin decreases the risk of recurrent myocardial infarction. This is supported by clinical studies, such as the Warfarin Re-Infarction Study [0m[1;32m([0m[32mWARIS[0m[1;32m)[0m[32m and the Warfarin, Aspirin, Re-Infarction Study [0m
[1;32m([0m[32mWARIS II[0m[1;32m)[0m[32m, which have shown that warfarin therapy can lead to a significant reduction in the risk of recurrent myocardial infarction. In the WARIS study, patients treated with warfarin showed a [0m[1;32m34[0m[32m% [0m
[32mrisk reduction in recurrent MI compared to placebo.[0m
